[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Investor Update - April 15, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Media News - April 15, 2024 Category: Pharmaceuticals Source Type: news
How to survive cancer, from the man who has beaten the disease five times
Bill Potts from Florida has survived cancer five times: thyroid cancer once and non-Hodgkin lymphoma four times. 'It sounds odd to even say those words. It's such a big number,' he said. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2024 Category: Consumer Health News Source Type: news
What to Expect From a Stem Cell Transplant
Stem cell transplantation, in combination with traditional treatments, can improve outcomes for patients with multiple myeloma and non-Hodgkin's lymphoma. (Source: WebMD Health)
Source: WebMD Health - March 12, 2024 Category: Consumer Health News Source Type: news
People with aggressive form of blood cancer given fresh hope as two new drugs set to be rolled out by the NHS
Two medications have been approved by the NHS's spending watchdog giving hope to patients living with a type of non-Hodgkin's lymphoma that kills four in ten within five years of diagnosis. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2024 Category: Consumer Health News Source Type: news
You Can ’t Have Healthy People On a Sick Planet
About a year ago, I was declared cancer-free after four months of chemotherapy at Providence St. John’s Health Center in Santa Monica, Calif. I had been diagnosed with low-grade B cell non-Hodgkin Lymphoma. This was not my first encounter with cancer. I’d had breast cancer a number of years prior, which was treated with radiation and then a full mastectomy. I realize I’m lucky. I had caring, attentive doctors and nurses who saved my life. I also realize how much progress has been made in cancer research and I am deeply grateful.
[time-brightcove not-tgx=”true”]
Yet despite that, cancer has...
Source: TIME: Health - January 12, 2024 Category: Consumer Health News Authors: Jane Fonda Tags: Uncategorized climate change Climate Is Everything Source Type: news
ASH 2023: New Geriatric Assessment Tools in DLBCL ASH 2023: New Geriatric Assessment Tools in DLBCL
Dr Suchitra Sundaram discusses the applicability of assessment tools to help reduce toxicities in the treatment of non-Hodgkin lymphoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
In a significant turn of events, Bayer AG BAYRY BAYZF emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin lymphoma. This win marked the end of a sequence of five consecutive trial defeats for the company regarding similar…#bayerag #brucejones #roundup #nonhodgkin #bayer #bayerreuters #monsanto (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Varicose veins could be a sign of CANCER, doctors warn - after treating 53-year-old woman with aggressive lymphoma
Doctors are warning that varicose veins could be a commonly missed sign of an aggressive form of non-Hodgkin lymphoma after treating a 53-year-old woman in China with the symptoms. (Source: the Mail online | Health)
Source: the Mail online | Health - December 8, 2023 Category: Consumer Health News Source Type: news
PET/CT predicts patient responses to CAR-T cell therapy
F-18 FDG-PET/CT scans may predict outcomes in patients with large B cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a presentation delivered November 30 at RSNA. Doris Leithner, MD, of Memorial Sloan-Kettering Cancer Center in New York City, presented a study in which researchers explored whether F-18 FDG-PET/CT imaging features acquired prior to treatment with CAR T-cell therapy were related to patient outcomes. They found the imaging features were strongly associated with death, relapse, and disease progression.“Our results demonstrate that quantitative PET imaging features in LBCL...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: Will Morton Tags: Nuclear Radiology Source Type: news
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Was This a Recurrence of Non-Hodgkin ’s Lymphoma or Something Else?
“Go to the emergency room,” the doctor told him after hearing of his trip and fever, rash and whole-body weakness. “You need to be seen.” (Source: NYT Health)
Source: NYT Health - November 20, 2023 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Chikungunya Virus Non-Hodgkin ' s Lymphoma Lyme Disease Joints (Body Part) Source Type: news
First in human trial of new drug raises hopes for patients with relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. (Source: World Pharma News)
Source: World Pharma News - November 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
